Activation of the Carboxypeptidase U (CPU, TAFIa, CPB2) System in Patients with SARS-CoV-2 Infection Could Contribute to COVID-19 Hypofibrinolytic State and Disease Severity Prognosis.

MLA

Claesen, Karen, et al. “Activation of the Carboxypeptidase U (CPU, TAFIa, CPB2) System in Patients with SARS-CoV-2 Infection Could Contribute to COVID-19 Hypofibrinolytic State and Disease Severity Prognosis.” Journal of Clinical Medicine, vol. 11, no. 6, Mar. 2022. EBSCOhost, https://doi.org/10.3390/jcm11061494.

APA

Claesen, K., Sim, Y., Bracke, A., De Bruyn, M., De Hert, E., Vliegen, G., Hotterbeekx, A., Vujkovic, A., van Petersen, L., De Winter, F. H. R., Brosius, I., Theunissen, C., van Ierssel, S., van Frankenhuijsen, M., Vlieghe, E., Vercauteren, K., Kumar-Singh, S., De Meester, I., & Hendriks, D. (2022). Activation of the Carboxypeptidase U (CPU, TAFIa, CPB2) System in Patients with SARS-CoV-2 Infection Could Contribute to COVID-19 Hypofibrinolytic State and Disease Severity Prognosis. Journal of Clinical Medicine, 11(6). https://doi.org/10.3390/jcm11061494

Chicago

Claesen, Karen, Yani Sim, An Bracke, Michelle De Bruyn, Emilie De Hert, Gwendolyn Vliegen, An Hotterbeekx, et al. 2022. “Activation of the Carboxypeptidase U (CPU, TAFIa, CPB2) System in Patients with SARS-CoV-2 Infection Could Contribute to COVID-19 Hypofibrinolytic State and Disease Severity Prognosis.” Journal of Clinical Medicine 11 (6). doi:10.3390/jcm11061494.